Last reviewed · How we verify
NCT07506304: BioACL
Biological Potentials in Arthroscopic All-inside Semitendinosus Anterior Cruciate Ligament Reconstruction
NA trial testing ACL reconstruction in Cruciate Ligament Reconstruction in 70 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | University Hospital Dubrava |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 September 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2032 |
Drugs / interventions tested
- ACL reconstruction
Conditions studied
- Cruciate Ligament Reconstruction — all drugs for Cruciate Ligament Reconstruction →
- Cruciate Ligament Rupture — all drugs for Cruciate Ligament Rupture →
- Cruciate Ligament Injury — all drugs for Cruciate Ligament Injury →
Sponsor
University Hospital Dubrava
Who can join
Adults 18 to 50, any sex, with Cruciate Ligament Reconstruction or Cruciate Ligament Rupture. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, double-blind, prospective single-center clinical trial evaluating the effect of biological augmentation in anterior cruciate ligament (ACL) reconstruction. The study compares standard all-inside semitendinosus ACL reconstruction versus biologically enhanced reconstruction incorporating muscle tissue preservation and autologous bone and fibrin augmentation. The primary aim is to assess whether biological augmentation improves graft healing, integration, and clinical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07506304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ACL reconstruction
Trials testing the same drug.
- NCT06167343 — Comparison of Semitendinosus and Quadriceps Grafts for Anterior Cruciate Ligament Reconstruction · NA · active not recruiting
- NCT05504018 — Clinical and Radiological Evaluation of ACL Reconstruction Results · NA · completed
- NCT05582226 — Augmentation of Anterior Cruciate Ligament Reconstruction Using Mesenchymal Stem Cells and Collagen Matrix Carrier · NA · unknown
- NCT05876013 — Reduced Knee Flexion Strength 18 Years After ACL Reconstruction in Hamstring Group Compared to Patellar Tendon Group · completed
- NCT05461625 — ACL Reconstruction With/Without ALL Reconstruction · NA · unknown
Other University Hospital Dubrava trials
Trials by the same sponsor.
- NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
- NCT07339449 — Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients · NA · recruiting
- NCT06960629 — The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) · enrolling by invitation
- NCT06969586 — The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy · enrolling by invitation
- NCT06646887 — Comparison of Different Electroporation Systems in the Ablation Treatment of Atrial Fibrillation · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07506304 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Dubrava
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07506304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing